← All indications
Testicular Neoplasms
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Subtype terms (1)
More specific conditions that are subtypes of Testicular Neoplasms in the MeSH hierarchy.
- Sertoli-Leydig Cell Tumor
1 drug approved
Drugs by status
Approved for this indication (8)
Phase 3 trials (32)
- levofloxacin
- tioguanine
- mercaptopurine
- aldoxorubicin
- urea
- bone autograft
- clofarabine
- prednisone
- doxorubicin
- paclitaxel
- naltrexone
- granisetron
- inotuzumab ozogamicin
- lerisetron
- leucovorin
- olanzapine
- vincristine
- pegaspargase
- carboplatin
- cyclophosphamide
- daunorubicin
- dasatinib
- testosterone
- methotrexate
- oxaliplatin
- moxifloxacin
- prednisolone
- sargramostim
- cytarabine
- dexamethasone
- +2 more
Phase 2 trials (70)
- methylprednisolone
- ibritumomab tiuxetan
- 99mtc ec20
- amifostine
- avelumab
- sorafenib
- bendamustine
- brentuximab vedotin
- busulfan
- lenalidomide
- durvalumab
- gemcitabine
- oblimersen sodium
- fluorouracil
- tacrolimus
- imatinib
- aldesleukin
- beclomethasone
- epirubicin
- Filgrastim
- nivolumab
- ixabepilone
- pembrolizumab
- msk-2206
- oprelvekin
- palbociclib
- peripheral blood lymphocytes
- carmustine
- ipilimumab
- sunitinib
- +40 more
Phase 1 trials (34)
- di-leu16-il2
- brodalumab
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- mkc1106
- devimistat
- guadecitabine
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- il-1
- methoxyamine
- alisertib
- morab-004
- ibrutinib
- trastuzumab
- prostate specific membrane antigen
- fowlpox-sargramostim
- recombinant fowlpox-cea(6d)/tricom vaccine
- interleukin-12
- sabarubicin
- bevacizumab
- tricom-cea(6d)
- y90 anti-cd45 monoclonal antibody bc8
- cea-loaded dendritic cells
- cediranib
- cefepime
- fludeoxyglucose f-18
- tislelizumab
- fapi-46
- hfb200301
- sgn-alpv
- +4 more
Organizations
Organization Involved with Phase 3 Indications (24)
- National Cancer Institute (NCI)
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- University of London
- Cornell University
- Eastern Cooperative Oncology Group
- Indiana University
- Lund University
- Norwegian University of Science and Technology
- Osaka University
- Southwest Oncology Group
- University Hospital of North Norway
- UNICANCER
- University of Bergen
- University of Birmingham
- University of California, San Francisco
- University of Copenhagen
- Uppsala University
- Institut Gustave Roussy
- Karolinska Institute
- City of Hope National Medical Center
- University of Gothenburg
- Linkoping University
- Norrlands University
Organization Involved with Phase 2 Indications (38)
- Amgen
- MedImmune
- Merck KGaA
- Sanofi
- Novartis
- Baxalta
- Endocyte
- Ziopharm
- Fondation Wygrajmy Zdrowie
- Medical Research Council
- National Cancer Institute, Slovakia
- Velindre NHS Trust
- University of Pennsylvania
- Emory University
- University of Washington
- Gottfried Wilhelm Leibniz Universität Hannover
- Hoosier Cancer Research Network
- Ludwig Institute for Cancer Research
- Swiss Group for Clinical Cancer Research
- University of Groningen
- University of Milan
- University of Oslo
- University of Southern California
- Wake Forest University
- University of Virginia
- University of Cambridge
- University of Basel
- Icahn School of Medicine at Mount Sinai
- Royal Marsden Hospital NHS Trust
- University of Texas at Houston
- +8 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)